Management of psychiatric and cognitive complications in Parkinson's disease
- PMID: 36280256
- DOI: 10.1136/bmj-2021-068718
Management of psychiatric and cognitive complications in Parkinson's disease
Abstract
Neuropsychiatric symptoms (NPSs) such as affective disorders, psychosis, behavioral changes, and cognitive impairment are common in Parkinson's disease (PD). However, NPSs remain under-recognized and under-treated, often leading to adverse outcomes. Their epidemiology, presentation, risk factors, neural substrate, and management strategies are incompletely understood. While psychological and psychosocial factors may contribute, hallmark PD neuropathophysiological changes, plus the associations between exposure to dopaminergic medications and occurrence of some symptoms, suggest a neurobiological basis for many NPSs. A range of psychotropic medications, psychotherapeutic techniques, stimulation therapies, and other non-pharmacological treatments have been studied, are used clinically, and are beneficial for managing NPSs in PD. Appropriate management of NPSs is critical for comprehensive PD care, from recognizing their presentations and timing throughout the disease course, to the incorporation of different therapeutic strategies (ie, pharmacological and non-pharmacological) that utilize a multidisciplinary approach.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: DW has received research funding or support from the Michael J Fox Foundation for Parkinson’s Research, Alzheimer’s Therapeutic Research Initiative, Alzheimer’s Disease Cooperative Study, International Parkinson and Movement Disorder Society, National Institutes of Health, Parkinson’s Foundation, US Department of Veterans Affairs, and Acadia Pharmaceuticals; honoraria for consultancy from Acadia Pharmaceuticals, Alkahest, Aptinyx, Cerevel Therapeutics, CHDI Foundation, Clexio, Clintrex LLC (Otsuka), EcoR1 Capital, Eisai, Ferring, Gray Matter Technologies, Great Lake Neurotechnologies, Intra-Cellular Therapies, Janssen, Merck, Sage, Scion, Signant Health, and Vanda; and license fee payments from the University of Pennsylvania for the QUIP and QUIP-RS. DA has received research support or honorariums from Astra-Zeneca, H Lundbeck, Novartis Pharmaceuticals, Sanofi, Evonik, Roche Diagnostics, and GE Health; and served as paid consultant for H Lundbeck, Eisai, Heptares, Mentis Cura, Eli Lilly, Cognetivity, Enterin, Acadia, Sygnature, Biogen, Cognetivity, EIP Pharma, and Acadia. RB reports honorariums to speak from Bial. She is supported by the Ministry of Health under Grant Number GR-2016-02361986. RD has received research support from the Michael J Fox Foundation for Parkinson’s Research, the Health Services Research and Development Division of the Veteran Affairs (VA) Administration, and the VA Office of Rural Health. JGG has received research funding or support from Acadia Pharmaceuticals, American Parkinson’s Disease Association, the Lewy Body Dementia Association, Michael J Fox Foundation for Parkinson’s Research, and Parkinson’s Foundation; and honorariums as a consultant, educational speaker, or reviewer from the International Parkinson and Movement Disorder Society, Parkinson’s Foundation, and Parkinson Study Group. SL is supported by a National Health and Medical Research Council Leadership Fellowship (1195830) and has received research funding or support from the Michael J Fox Foundation for Parkinson’s Research, Pharmaxis, and Acceler8.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical